A detailed history of New York State Common Retirement Fund transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, New York State Common Retirement Fund holds 8,646 shares of JANX stock, worth $485,386. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,646
Previous 11,546 25.12%
Holding current value
$485,386
Previous $484,000 18.8%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$35.29 - $50.26 $102,341 - $145,754
-2,900 Reduced 25.12%
8,646 $393,000
Q2 2024

Jul 31, 2024

BUY
$35.12 - $64.78 $151,261 - $279,007
4,307 Added 59.5%
11,546 $484,000
Q1 2024

May 07, 2024

BUY
$7.93 - $49.75 $17,358 - $108,902
2,189 Added 43.35%
7,239 $273,000
Q4 2023

Feb 01, 2024

SELL
$5.85 - $11.7 $204 - $409
-35 Reduced 0.69%
5,050 $54,000
Q3 2023

Nov 07, 2023

BUY
$9.56 - $14.0 $525 - $770
55 Added 1.09%
5,085 $51,000
Q2 2023

Aug 07, 2023

SELL
$11.08 - $15.92 $91,055 - $130,830
-8,218 Reduced 62.03%
5,030 $60,000
Q1 2023

May 02, 2023

BUY
$11.25 - $22.21 $146 - $288
13 Added 0.1%
13,248 $160,000
Q4 2022

Jan 30, 2023

SELL
$11.1 - $18.26 $266 - $438
-24 Reduced 0.18%
13,235 $174,000
Q3 2022

Nov 08, 2022

BUY
$10.82 - $16.84 $56,761 - $88,342
5,246 Added 65.47%
13,259 $180,000
Q2 2022

Aug 04, 2022

SELL
$9.52 - $15.65 $71,476 - $117,500
-7,508 Reduced 48.37%
8,013 $98,000
Q1 2022

May 05, 2022

BUY
$13.24 - $20.24 $79,440 - $121,439
6,000 Added 63.02%
15,521 $223,000
Q4 2021

Feb 02, 2022

BUY
$15.44 - $27.32 $111,492 - $197,277
7,221 Added 313.96%
9,521 $188,000
Q3 2021

Nov 02, 2021

BUY
$20.7 - $34.69 $47,610 - $79,787
2,300 New
2,300 $50,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.34B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.